Gene · 2642
Papers2,157
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,157
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. | Pharmacol Res | 2026 | 42556625 | PubTator, text mining | PubMed |
| Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase. | Sci Adv | 2026 | 42555719 | PubTator, text mining | PubMed |
| Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH. | Hepatology | 2026 | 42545725 | PubTator, text mining | PubMed |
| Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. | J Am Heart Assoc | 2026 | 42535526 | PubTator, text mining | PubMed |
| Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. | J Comput Aided Mol Des | 2026 | 42530676 | PubTator, text mining | PubMed |
| Novel Compounds with Aryl Linkers as Glucagon Receptor Agonists for Treating Type 2 Diabetes Mellitus and Obesity. | ACS Med Chem Lett | 2026 | 42445042 | PubTator, text mining | PubMed |
| Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate. | ACS Med Chem Lett | 2026 | 42445014 | PubTator, text mining | PubMed |
| Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future. | Liver Int | 2026 | 42438128 | PubTator, text mining | PubMed |
| Occurrence and toxicity mechanisms of hexafluoropropylene oxide dimer acid (HPFO-DA, GenX) in aquatic species. | Environ Sci Process Impacts | 2026 | 42429221 | PubTator, text mining | PubMed |
| Identification of glicentin as a low-potency glucose-dependent insulinotropic polypeptide receptor agonist. | Peptides | 2026 | 42425317 | PubTator, text mining | PubMed |
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. | Diabetes Obes Metab | 2026 | 42410325 | PubTator, text mining | PubMed |
| Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. | Front Pharmacol | 2026 | 42394981 | PubTator, text mining | PubMed |
| GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies. | Pharmacol Res | 2026 | 42379432 | PubTator, text mining | PubMed |
| Mitochondrial Alterations and CKD: A Review. | Am J Kidney Dis | 2026 | 42331132 | PubTator, text mining | PubMed |
| Transcriptomic and differential gene analysis investigating the differences in biological behaviour between subtypes of feline alimentary lymphoma. | Front Vet Sci | 2026 | 42290793 | PubTator, text mining | PubMed |
| Systematic Design of PLGA Nanoparticles for Long-Acting Delivery of a Dual GLP-1/Glucagon Receptor Coagonist Peptide (SAR425899) via Phase Inversion Nanoencapsulation. | Langmuir | 2026 | 42289975 | PubTator, text mining | PubMed |
| Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials. | J Investig Med | 2026 | 42257390 | PubTator, text mining | PubMed |
| Survodutide Once Weekly for the Treatment of Adults with Obesity. | N Engl J Med | 2026 | 42253238 | PubTator, text mining | PubMed |
| Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2026 | 42252333 | PubTator, text mining | PubMed |
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. | Lancet | 2026 | 42250575 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2642/papers?page=2